New York State Common Retirement Fund grew its position in Exelixis, Inc. (NASDAQ:EXEL) by 11.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 752,764 shares of the biotechnology company’s stock after acquiring an additional 76,367 shares during the period. New York State Common Retirement Fund owned about 0.25% of Exelixis worth $18,239,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of EXEL. First Quadrant L P CA raised its position in shares of Exelixis by 6,771.4% during the 3rd quarter. First Quadrant L P CA now owns 402,528 shares of the biotechnology company’s stock worth $9,753,000 after purchasing an additional 396,670 shares during the last quarter. Prudential Financial Inc. raised its position in shares of Exelixis by 262.0% during the 2nd quarter. Prudential Financial Inc. now owns 627,530 shares of the biotechnology company’s stock worth $15,456,000 after purchasing an additional 454,197 shares during the last quarter. GAM Holding AG acquired a new position in shares of Exelixis during the 2nd quarter worth about $1,256,000. Macquarie Group Ltd. acquired a new position in shares of Exelixis during the 2nd quarter worth about $3,449,000. Finally, Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Exelixis by 583.1% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 659,592 shares of the biotechnology company’s stock worth $16,246,000 after purchasing an additional 563,040 shares during the last quarter. Institutional investors and hedge funds own 81.19% of the company’s stock.

In other news, EVP Jeffrey Hessekiel sold 27,302 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $24.28, for a total value of $662,892.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stelios Papadopoulos sold 72,210 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $27.76, for a total transaction of $2,004,549.60. The disclosure for this sale can be found here. In the last three months, insiders sold 409,512 shares of company stock valued at $10,836,442. Corporate insiders own 5.10% of the company’s stock.

Shares of Exelixis, Inc. (NASDAQ EXEL) opened at $25.95 on Friday. The company has a market cap of $7,710.00, a PE ratio of 52.63, a price-to-earnings-growth ratio of 1.20 and a beta of 1.89. Exelixis, Inc. has a 1-year low of $14.22 and a 1-year high of $32.50.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.18. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The company had revenue of $152.50 million during the quarter, compared to the consensus estimate of $104.91 million. During the same quarter in the prior year, the firm earned ($0.04) EPS. Exelixis’s quarterly revenue was up 145.2% on a year-over-year basis. research analysts expect that Exelixis, Inc. will post 0.49 earnings per share for the current year.

Several research firms recently weighed in on EXEL. Needham & Company LLC upped their price target on shares of Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Oppenheimer restated a “hold” rating on shares of Exelixis in a research report on Monday, September 25th. Royal Bank of Canada upped their price target on shares of Exelixis from $33.00 to $39.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 17th. Stifel Nicolaus reiterated a “hold” rating and issued a $26.00 price objective on shares of Exelixis in a report on Tuesday, October 17th. Finally, SunTrust Banks increased their price objective on shares of Exelixis from $32.00 to $35.00 and gave the company a “buy” rating in a report on Monday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Exelixis has an average rating of “Buy” and an average target price of $31.38.

TRADEMARK VIOLATION NOTICE: “New York State Common Retirement Fund Has $18.24 Million Holdings in Exelixis, Inc. (EXEL)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/new-york-state-common-retirement-fund-has-18-24-million-holdings-in-exelixis-inc-exel/1764814.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.